Screw it, double down man.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Dayton has proven he is anti business with this last move. The only thing he does is fleece millions from taxpayers to build sports stadiums. These folks have paid for mineral rights, DNR signed off on it an Dayton says no way. Has he lost his marbles????!!! It's like a Mcdonalds is building store in St. Paul and Burger King wants to build a store in Minneapolis but the Gov. Says Burger King can't build on the land they ALREADY LEASED. The most anti business administration I've seen. He either has lost it or he is afraid to make decisions. Call the Governors office and explain have crazy this is!!
Kind of agree. The lawyer costs come out of the settlement so the sooner they end this the more CVM pockets and the less the legal fees are.
I am still thinking that it's in the best interest for the former CRO to settle out of court before they see a day in court. That said, would CVM's lawyers advise Geert to take a settlement or go for the jugular in front of the arbiter.
I am
I know owners of this stock that totals over 250,000 shares. They are holding as well. All obviously disappointed with the pricing going into Feb but are vigilant going into the DNR's decision. I can tell you, their minds will change if this is delayed by the DNR anymore.
The 30,000 share dump was an hour late today.
Looks like it works.
http://www.twincities.com/2016/02/04/weighing-copper-dayton-pressured-on-second-iron-range-mine/
Even Democrats can't get senile Dayton to cooperate........
Yup, arbitration. Looking for a firm date.
Couldn't get a new Governor soon enough.
From Dayton's office Tonight, 2-4-16
Dayton, in a statement relayed through his communications office Thursday evening, said he won't approve any Twin Metals issues until the PolyMet project finishes going through the regulatory process.
"I do not intend for my administration to proceed on any aspect of the Twin Metals project until after the PolyMet EIS adequacy determination and possible subsequent permitting processes are resolved," the governor said.
The access agreement would provide "Twin Metals access to specific state lands for the purpose of conducting environmental, mineral assessment and geotechnical due-diligence activities in support of the potential mine" the company said in a statement.
Copper mining supporters say DNR agency staff has signed-off on the access but that the final approval has been sitting on the governor's desk without action for several months.
"We have a routine regulatory agreement that's been approved by the regulatory agency but which apparently has become a political issue and can't get past the governor," said Frank Ongaro, director of Mining Minnesota, the Duluth-based copper industry trade group.
Dayton has received intense political pressure from both sides of the current PolyMet copper mine project near Hoyt Lakes. The final environmental review of the project is expected to be approved this month, after which the company will apply for state permits which will get final approval, or not, from Dayton's agency chiefs.
Republicans and Iron Rangers have urged Dayton to approve the PolyMet project with its potential 300 jobs as a boon to regional economic diversification. But environmental groups have urged him to veto the project because of its potential threat of polluting waterways.
Dayton has called PolyMet the hardest decision of his two terms in office. But Twin Metals could be even more controversial because it sits adjacent to the famed Boundary Waters Canoe Area Wilderness, a federally protected, lake-studded region that's cherished by conservationists worldwide.
Timberjay is well known for hit peices...
Still hard to believe this is down with metal prices rebounding so much today. Other miners up 10-22% across the board.
My bet is there is another rights offering as well. Before summer.
Gets ya thinkin....
That's about as promising as it's going to get.
Department of Natural Resources Commissioner Tom Landwehr plans to decide "about February" whether to certify as adequate the final environmental impact statement on the proposed PolyMet copper-nickel mine. He has already said
HE EXPECTS TO APPROVE
the 3,576-page document. Once he does and federal agencies sign off, PolyMet Mining Corp. plans to quickly start applying for the permits it needs to build Minnesota's first copper-nickel mine.
All that being said I am confident the DNR will approve the EIS this month.
Because this is the United States where Government always gets in the way. Our "leaders" have lost touch. Like I said, Dayton's quote is he is more concerned about "his legacy" than anything right now. Whatever that actually means. It would be Democrat "suicide" if they go against it. Northern MN would go Republican over night.
That is the truth.
He has the power to push it in a direction he feels it should. However too much melding could bring lawsuits.
The Governor sits in a hospital bed because he fainted giving a speech to his big money supporters. But seriously, he is a wild card. He keeps talking about "his" legacy when really it should be about the People of Minnesota. Remember, his ex wife is a Rockefeller who is a board member of one of the largest anti development groups in MN. Funny because her grandfather got the money she now controls fleecing the people of MN in horrible land, timber, iron ore, railroad, and shipping deals 100 years ago. Dayton is a billionaire who has no real touch with reality. He was asked what a gallon of milk cost and he responded $12. Then his campaign manager said not to quote him because he hasn't purchased his own groceries.... Ever.!
Pretty much the only miner not up over 5% today. Copper charging up...
Buy blocks*
I would like to see management but blocks of shares at these levels. I know hey are not selling and that shows something but buying shows a lot more....
Thrilling Phase III Cancer Immunotherapy Comeback and the Significance of the CEO's 3 Million Share Purchase
WEST HARRISON, NY / ACCESSWIRE / February 4, 2016 / A comeback management team has transformed CEL-SCI Corporation (NYSE MKT :CVM) into a classic special situation. That definition is a stock whose price should rise regardless of the overall stock market direction because of its intrinsic value and momentum.
During a recent presentation CEL-SCI CEO Geert Kersten quipped, "Among a class of college students in Economics 101 no one would ever believe the kind of stuff that happens to biotech companies. No one would ever invest if they knew, right? But the flip side is that no where can you make as much money as in small biotech companies which become successful!"
"Sheer persistence," is Kersten's explanation of CEL-SCI's almost miraculously survival. "My management team has been with me for 20 years. Where do you still find that? What holds us together is our data-driven belief that our Multikine drug treatment works."
After significant setbacks, CEL-SCI is approaching the finish line for its world's largest head and neck cancer immunotherapy Phase III study. Almost 700 patients are enrolled at 84 sites in 24 countries including in the U.S., Canada, Israel and parts of Europe and Asia. However, CEL-SCI's recent market cap of $62 million is a tiny fraction of the billions of some earlier stage Phase I or Phase II rivals. Last month to demonstrate his belief things are going well at last , the CEO made his biggest single personal purchase of 3 million shares valued about $1.1 million.
CEL-SCI's unique Phase III study is pioneering injecting its Multikine drug regime for three weeks into the four week window before traditional surgery, radiation and/or chemotherapy. In contrast, other cancer immunotherapy companies, which require much longer treatment times, must aim to boost the immune system after the tumor has recurred. Unfortunately that is also when the immune system may have been debilitated by the toxicity from the earlier surgery, radiation and chemotherapy.
Full enrollment of its trial 880 patients is expected in 2016 with possible study completion in late 2017. If a 10% improvement in patient survival versus the current standard of head and neck cancer care is achieved, CEL-SCI expects to submit a Biologics License Application to the FDA seeking approval of its Multikine drug regime. Success would offer the potential to become the fourth standard of care for head and neck cancer, preceding and joining surgery, chemotherapy and radiation. That would involve about 6% of the world's solid cancers.
Anyone wanna take a guess on when the DNR will publish their EIS decision? I'm saying the 19th of Feb.
I'd love to see it close above .90 but it looks like it's having trouble. Zinc making huge runs, platinum is up, copper making a good push.
Folks, DNR decision is less than 3 weeks away.......!
Copper continuing it's rebound.
Maybe the Chamber of Commerce Forum had an effect.
CEL-SCI to Present at 18th Annual BIO CEO & Investor Conference
VIENNA, Va.--(BUSINESS WIRE)--
CEL-SCI Corporation (NYSE MKT: CVM) announced that Geert Kersten, Chief Executive Officer, will be presenting at the 18th Annual BIO CEO & Investor Conference on Tuesday, February 9, 2016 at 11:00 a.m. Hosted by the Biotechnology Industry Organization (BIO), the 18th Annual BIO CEO & Investor Conference will take place February 8-9 at the Waldorf Astoria in New York City.
A live audio webcast of the presentation and replay will be available under the investor relations section of CEL-SCI's website at www.cel-sci.com/investor_relations.html. The replay of the presentation will be available approximately 1 hour after the presentation and is accessible until May 8, 2016.
About the BIO CEO & Investor Conference
Now in its eighteenth year, the BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded and select private biotech companies. Each year this conference provides a neutral forum where institutional investors, industry analysts, and senior biotechnology executives have the opportunity to shape the future investment landscape of the biotechnology industry.
About CEL-SCI Corporation
CEL-SCI is a Phase 3 immunotherapy company with platform technologies that can potentially treat a variety of cancers and viral diseases. We believe that one must activate the immune system BEFORE radiation and chemotherapy, and even before surgery, to achieve the best results in the greatest number of patients. CEL-SCI is conducting a Phase 3 trial in 24 countries of Multikine (Leukocyte Interleukin Injection) for the treatment of head and neck cancer, which accounts for about 6% of cancers globally and a $6 billion market. Almost 700 patients are already enrolled in this study. CEL-SCI is also testing Multikine with the U.S. Navy in HIV infected patients with HPV related diseases. CEL-SCI has development partnerships with Teva Pharmaceuticals, Orient EuroPharma of Taiwan, Ergomed and the NIH. The Company operates its own 75,000 sq. ft. manufacturing facility and produces Multikine for its clinical trials. When fully built out, this facility will have the capacity to supply about $3 billion worth of Multikine annually. CEL-SCI is also developing its pre-clinical L.E.A.P.S. (Ligand Epitope Antigen Presentation System) technology as a potential vaccine for the treatment of rheumatoid arthritis.
Thoughts on if Geert will try any sort of media blitz regarding Zika virus and L.E.A.P.S.? First case out of Texas today.
I know there was mention during H1N1...? Curious to me.
Ending on high of the day.
Fairly strong for a day the rest of the market if red.
Approaching 200 day MA @ .95
Pushing through 50 day MA......?
Ergomed eyes more drug deals as revenues rise
Pharma services specialist Ergomed (LON:ERGO) lifted by revenues by 25% in 2015 with orders also rising strongly.
The company splits its business between services supply and drug co-development deals.
Revenues for 2015 were approximately £29mln (£24mln including acquisition PrimeVigilance on a pro-forma basis).
New contracts during the year totalled £28mln, including several repeat orders for full service clinical studies, full service pharmacovigilance projects and medical information services.
Orders at the year-end were approximately £59mln.
A co-development deal with the Swedish biotech company, Dilaforette in sickle cell anaemia also started Phase II clinical studies.
All told, Ergomed has stakes in five drugs in the later stage of development.
Miroslav Reljanovic, chief executive said: “Our co-development portfolio is maturing and we are looking forward to our partners' late stage clinical data to be announced later in 2016.
“We are in active discussions with a number of partners and expect to announce new deals in 2016,” he added.
A significant proportion of revenue was already secured for 2016 and allied to the late stage co-development pipeline, he was confident about the future, said Reljanovic.
In 2016, results are due from the Phase III trial of Aeterna Zentaris's Zoptrex in endometrial cancer, Phase IIa results of Ferrer's insomnia treatment lorediplon (fourth quarter).
Cel-Sci's 880-patient Phase III head and neck trial of Multikine is also due to complete recruitment in 2016.
http://www.proactiveinvestors.co.uk/companies/news/121982/ergomed-eyes-more-drug-deals-as-revenues-rise-121982.html
Agree again, the beginning of the day sale, pretty much everyday, is the only downward pressure. Otherwise this thing rises on any buying.
29 enrolled
697 total
Yup, those are the reasons.